‘Buy the Dip,’ Says Mizuho’s Top Analyst About UnitedHealth Stock (UNH)

UnitedHealth Group (UNH) has struggled this year, with shares down about 50% year-to-date. The drop has been driven by rising costs in its Medicare Advantage business, weak Q2 results, a surprise CEO departure, and a federal probe into its billing practices. The latest quarterly miss added to investor concerns. Even so, Mizuho Top analyst Ann Hynes kept her Buy rating, saying the recent weakness could present a buying opportunity for long-term investors. The 4.5-star analyst still sees UnitedHealth as a leader in the managed care industry, but she trimmed her price target to $300 from $350 to reflect a more cautious outlook.

Analyst Views about UNH Stock

Hynes noted that UnitedHealth reinstated its 2025 earnings guidance but made important changes to its long-term goals. The company cut Optum Health’s margin target to 6–8% from 8–10% and Medicare Advantage margins to 2–4% from 3–5%. It did not reaffirm its prior 13–16% long-term earnings growth goal but also did not withdraw it.

The analyst expects pricing pressure and high medical cost trends to continue into 2026. She also flagged underperformance in Optum Health’s value-based care and Optum Insight segments. Reflecting these headwinds, she cut her adjusted EPS estimates by 14% for 2025, 20% for 2026, and 24% for 2027.

Hynes also warned of potential risks from the expiration of enhanced premium tax credits and upcoming Medicaid changes under the One Big Beautiful Bill Act, which could shift membership and weigh on margins.

Nevertheless, she sees UnitedHealth’s scale, market position, and diversified business as key strengths, and believes the stock’s valuation remains attractive.

Is UNH a Good Buy Right Now?

Turning to Wall Street, UNH stock has a Moderate Buy consensus rating based on 18 Buys, four Holds, and two Sells assigned in the last three months. At $312.65, the average UnitedHealth stock price target implies a 24.62% upside potential.

See more UNH analyst ratings